Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis reports positive Cosentyx data for ankylosing spondylitis

Novartis reports positive Cosentyx data for ankylosing spondylitis

9th November 2015

Novartis has announced clinical trial data demonstrating the efficacy of Cosentyx in the treatment of ankylosing spondylitis over a two-year period.

Late-breaking results from the MEASURE 1 trial showed that up to 80 percent of patients with ankylosing spondylitis experienced no radiographic progression in the spine on X-ray assessment.

This is the first time that data on structural spinal progression in ankylosing spondylitis have been presented for an interleukin-17A inhibitor of this kind. In addition, it showed a sustained response in improvements of signs and symptoms, physical function and quality of life over the two years.

This makes Cosentyx the first IL-17A inhibitor and biologic treatment – other than anti-TNFs, the current standard of care – to demonstrate efficacy in phase III ankylosing spondylitis studies.

Vasant Narasimhan, global head of development at Novartis Pharmaceuticals, said: "Many patients with ankylosing spondylitis will go on to experience stiffening of the spine. Cosentyx has shown the potential to reduce structural damage of the spine in ankylosing spondylitis patients across two years."

This comes after the European Medicines Agency's Committee for Medicinal Products for Human Use recommended Cosentyx as a treatment for ankylosing spondylitis and psoriatic arthritis last month.ADNFCR-8000103-ID-801805237-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.